Northwest Biotherapeutics Inc. announced a settlement regarding litigation over 2020 option awards, with the company receiving $2.25 million from insurers and cancelling 17% of the contested options. The settlement date was December 12, 2025, and a court hearing for attorney fees is set for March 16, 2026.